European Companies Search Engine
EU funding (€1,500,000): Deconstructing Intestinal Immune Tolerance Hor 20 Sept 2023 EU Research and Innovation programme "Horizon"
Overview
Text
Deconstructing Intestinal Immune Tolerance
The intestinal tract is the main site of nutrient absorption and faces constant exposure to complex environmental stimuli. Intestinal barrier integrity and functionality are safeguarded by the intestinal immune system, which must balance its pro- and anti-inflammatory activities to provide protection from pathogenic microorganisms while preventing unwanted reactivity to self-antigens, commensal microbes, and dietary components. The intestinal immune environment can be viewed as a multicellular network in which the identity and function of individual cells is intrinsically programmed by transcription factors (TFs) that regulate their gene expression. These cells in turn can respond to signals in their environment and impact the behavior of their neighbors, which over time drives changes in tissue physiology. Conventional genetic knockout approaches offer insufficient temporal resolution to dissect these regulatory layers. In this proposal, we will employ chemical genetic protein degradation using the auxin-inducible degron 2 (AID2) system to deconstruct the intestinal immune regulatory network. These studies will focus on the role of Foxp3+ regulatory T (Treg) cells, whose continuous immunosuppressive activity is required to prevent the onset of intestinal inflammation. In Aim 1, we will use newly generated mouse models to probe the direct gene regulatory functions of key TFs that define intestinal Treg cell subsets. In Aim 2, we will fluorescently label intestinal Treg cells and rapidly degrade the TFs that confer their suppressive activity to study their functionality in situ. Finally, in Aim 3, we will use a reversible mosaic protein degradation strategy to study how the signals that precede and promote intestinal Treg cell differentiation shape the developing intestinal immune system. Together, these studies will provide fundamentally new insights into the regulatory network underlying intestinal immune tolerance.
Funded Companies:
| Company name | Funding amount |
| Forschungsinstitut FUR Molekulare Pathologie GmbH | €1,500,000 |
Source: https://cordis.europa.eu/project/id/101116251
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Forschungsinstitut für molekulare Pathologie GmbH, Vienna, Austria.